Skip to content

Study · Animal study (in vivo) · 1986

1 result

Potentiation of dermorphin-induced antinociception by peptidase inhibitors.

Sakurada S, Watanabe H, Sakurada T, Andoh R, Kisara K, Sasaki Y, Suzuki K

The Journal of pharmacy and pharmacology1 Mar 1986Cited by 8 (Europe PMC)

PMID2871164 (opens in a new tab)DOI10.1111/j.2042-7158.1986.tb04553.x (opens in a new tab)PepBankPUB-02871164
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In animal tests, dermorphin had greater antinociceptive potency than its N-terminal tetrapeptide metabolite.

    In plain wordsIn animal tests, dermorphin reduced pain responses more potently than its N-terminal tetrapeptide metabolite.

    Peptide
    Dermorphin
    Outcome
    IncreaseAntinociceptive potency
    Study

    n: not reported in source

    Comparator
    N-terminal tetrapeptide
    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    Dose not stated · intracerebroventricularAs given in this study.

    Measurements

    Relative potency of tetrapeptide
    84 times less potent
    than parent heptapeptide

    Source sentences

    Summary
    Moreover, the N-terminal tetrapeptide was 84 times less potent than its parent heptapeptide when administered intracerebroventricularly.
    1 context sentence
    Summary · context
    In addition, the potency of dermorphin was compared with that of one of its metabolites, N-terminal tetrapeptide (Tyr-D-Ala-Phe-Gly), by using the tail pressure test.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.